Physician profile
Benjamin Enciso
NPI 1932692597
$2,156.70
in general payments reported to CMS, 2019-2025
14 companies · $251 in 2025
The $251 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $225 · 2022: $314 · 2023: $609 · 2024: $648 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $537.55 | 2023-2024 | Phasix Mesh |
| W. L. Gore & Associates, INC. | $446.60 | 2023-2025 | Gore Seamguard Bioabsorbable Staple Line Reinforce, Gore Enform Preperitoneal Biomaterial, Gore Bio-A Tissue Reinforcement |
| Stryker Corporation | $372.45 | 2021-2023 | Spy-Phi System |
| Atricure, INC. | $150.10 | 2023 | |
| Kerecis Limited | $143.79 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Aroa Biosurgery Incorporated | $123.07 | 2022 | |
| Kci USA, INC. | $96.29 | 2022 | |
| Teleflex LLC | $94.93 | 2022 | |
| Veloxis Pharmaceuticals, INC. | $94.57 | 2019 | |
| Lilly USA, LLC | $28.93 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $18.38 | 2023 | Xarelto |
| Currax Pharmaceuticals LLC | $17.98 | 2025 | Contrave |
| Inari Medical, INC. | $17.09 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Applied Medical Technology INC | $14.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Enciso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.